Kolmar Korea has discovered the hair loss mitigation effects of Sophora flavescens extract and has presented their findings at an international academic conference, marking the industry’s first such patent application. The discovery and subsequent presentation have garnered global attention.On April
Bereum, a pioneering force in postbiotic, has recently inked a strategic collaboration with Hyundai Corporation Group to venture into the North American market. The contract, valued at $10 million, marks a significant milestone in the company's journey, positioning it as the sole domestic competitor
Kolmar Korea has discovered the world’s first microbiome (in-human microbiome) that suppresses skin aging caused by ultraviolet exposure. In addition, the related research findings were published in international SCI-level journals, and its research achievements were recognized worldwide.Kolmar Kore
Celltrion announced on Feb. 6 that Rani Therapeutics (Rani) in the United States has confirmed positive topline results in the Phase 1 clinical trial of oral ustekinumab (development name: RT-111). RT-111 is an oral formulation of Celltrion’s Stelara biosimilar, CT-P43, currently under development.I
Samsung Biologics is expected to continue to post the highest growth rate in the global contract development manufacturing organization (CDMO) industry this year after posting record-high business results in 2023.A consensus forecast for Samsung Biologics’ revenue growth was 22 percent last year, ac
Celltrion announced on Sept. 19 that it is focusing on securing various platforms and pipelines including oral antibody therapeutics, antibody drug conjugates (ADCs), new antibody drugs, bispecific antibodies, microbiomes and anti-cancer virus platforms through development and research as well as op
Postbiotics specialist company bereum Co., Ltd. (CEO Han Kwon-il) announced on July 27 that it has registered a U.S. patent for the prevention and improvement of muscle loss from the Enterococcus faecalis bacterial strain (EF-2001).As we age, we become weaker and slower than when we were young. This
CJ Bioscience announced on July 25 that it has confirmed a total of 15 microbiome drug pipelines, setting the record for the highest number globally among microbiome drug development companies.In March, CJ Bioscience commenced pipeline analysis work after acquiring promising drug candidates from 4D
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.1Q23 operating loss decreases on cost control despite sales dropPsomagen continued in the red in 1Q23 with sales of USD6.52mn (-11.2% YoY) on standalone basis. Sales fell as orders were slashed by a m
CJ Bioscience, an affiliate of CJ CheilJedang, announced on April 13 that it would present a poster of the results of preclinical trials on CJRB-101 at the American Association for Cancer Research (AACR) 2023, one of the world’s top three cancer societies. CJRB-101 is a new drug candidate (pipeline)
bereum, a company specializing in heat-killed lactic acid bacteria postbiotics, and Dx&Vx, a bio-health care company, signed an MOU on April 5th. Through this agreement, the two companies plan to target the microbiome market by conducting joint research, such as analyzing not only lactic acid bacter
CJ CheilJedang’s CJ Bioscience announced on March 27 that it has signed an agreement to acquire promising drug candidates and platform technologies from 4D Pharma, a UK- and Ireland-based microbiome company.The newly introduced drug candidates total nine, targeting solid cancer, digestive diseases,
Kolmar Korea announced on Jan. 19 that its research on correlations between androgenic hair loss and intestinal and scalp microbiomes has been published in the Frontiers in Microbiology journal.Androgenic hair loss is one of the most frequent types of hair loss and is characterized by hair becoming
LG Household & Health Care has established a microbiome research center in Otaru, Hokkaido of Japan to develop microbiome cosmetics for advanced overseas markets such as North America and Japan, the company announced on May 13.Hokkaido is famous not only for its clean natural environment, but for go
A research team led by Jo Hyun-su at the Korea Research Institute of Bioscience and Biotechnology discovered that a substance from intestinal microorganisms kills colon cancer cells. According to the team, the discovery is expected to make a great contribution to microbiome-based colon cancer cure d
CJ CheilJedang launched CJ Bioscience, a subsidiary specializing in pharmaceuticals and healthcare, on Jan. 5. The new company is a combination of CJ CheilJedang's red bio unit and Chunlab, a microbiome company acquired by CJ CheilJedang in October 2021.At the launching ceremony, CJ Bioscience p
CJ CheilJedang announced on Nov. 8 that it will acquire 50,807 shares of Batavia Biosciences, a Dutch biotech (BT) company, for 267.7 billion won to enter the global cell and gene therapy (CGT) contract development and manufacturing market.The scheduled acquisition date is Dec. 31. CJ CheilJedang wi
Corporate interest in microbiomes is growing as microorganisms in the human body such as germs, viruses, and molds can be used to treat cancer and other diseases.Accordingly, companies that used to make health enhancement foods and cosmetics using microbiomes are starting to develop treatments for d
Dermocosmetic products are fueling the growth of Dongkook Pharmaceutical.Sales of Centellian 24, the company's dermocosmetic brand, nearly doubled from 53.4 billion won in 2018 to 105.4 billion won in 2020. Considering that the company's total sales swelled from 400.8 billion won to 559.1 bi
Genome and Co., a leading global microbiome anti-cancer drug development company, signed a second clinical trial collaboration and supply agreement (CTCSA) with Merck KGaA of Germany and Pfizer Inc. with the aim of developing the world’s first immuno-oncology microbiome therapeutic.The collaboration